Although the pathogenic role of HSD17B13 genetic variants in MASLD has not yet been completely understood, several reports have demonstrated their relation to the clinical spectrum of MASLD. This evidence concerns the gene HSD17B13 and metabolic dysfunction-associated steatotic liver disease.